Arcus Biosciences, INC Form 4 insider transactions

Arcus Biosciences' President, Jaen Juan C., reports the acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Robert Goeltz II, CFO of Arcus Biosciences, sold 3,594 shares of common stock on December 31, 2024, at a price of $15 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, sold 3,007 shares of common stock at $15.17 per share on December 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 27,501 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Arcus Biosciences' General Counsel, Carolyn C. Tang, sold 11,339 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Arcus Biosciences CEO Terry Rosen sold 37,882 shares to cover tax obligations and adjusted his holdings by 1,547,062 shares due to a domestic relations order.

Dimitry Nuyten, Chief Medical Officer of Arcus Biosciences, sold 7,856 shares of common stock to cover tax obligations related to vesting RSUs.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 10,099 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 2,969 shares of common stock to cover tax obligations related to vested Restricted Stock Units (RSUs).

Arcus Biosciences President, Juan C. Jaen, sold 17,286 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 201 shares of common stock at $15.32 per share, according to a recent SEC filing.

Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, disposed of shares to cover tax obligations related to vesting RSUs.

Dimitry Nuyten, Chief Medical Officer of Arcus Biosciences, reports a transaction involving common stock to cover tax obligations related to vested RSUs.

Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, reports selling 1,357 shares of common stock at $14.97 per share on August 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences CEO Terry Rosen disposed of 12,670 shares of common stock on June 15, 2024, to cover tax withholding obligations related to the vesting and settlement of RSUs.

Arcus Biosciences' President, Jaen Juan C., reports a transaction involving common stock due to the net settlement of RSUs for tax obligations.

Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, reports a transaction involving common stock due to tax withholding obligations and employee stock purchase plan.

Carolyn C. Tang, General Counsel of Arcus Biosciences, reports the disposition of 4,182 shares of common stock to cover tax obligations related to RSU vesting, while also increasing holdings through an employee stock purchase plan.

Director Yasunori Kaneko reports acquisition of restricted stock units and stock options, along with adjustments to holdings through associated entities.

Director David L. Lacey of Arcus Biosciences received stock options and restricted stock units (RSUs) on June 6, 2024, according to a Form 4 filing with the SEC.

Director Kathryn Falberg reported the acquisition of restricted stock units and stock options in Arcus Biosciences.

Director Patrick Machado reported the acquisition of restricted stock units and stock options in Arcus Biosciences on June 6, 2024.

Director Andrew Perlman reports receiving stock and option grants from Arcus Biosciences.

Director Antoni Ribas reported the acquisition of restricted stock units and stock options in Arcus Biosciences.

Director Nicole Lambert reported the acquisition of 8,400 shares of common stock and 24,000 stock options, along with the disposal of 24,000 shares of common stock.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 11,551 shares of common stock at an average price of $17.55 on March 27, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold shares to cover tax withholding obligations related to vesting RSUs, as per the company's equity administration policy.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, executed sales of common stock on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences' President, Juan C. Jaen, sold shares of common stock on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.